HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Key Points

• HC Wainwright raised its FY2030 EPS forecast for Acrivon Therapeutics to $0.14 from $0.13, while analysts currently expect a full-year loss of $1.92 per share.
• Acrivon reported a quarterly loss of $0.43 per share, beating consensus expectations for a $0.50 loss. Analyst sentiment remains a “Moderate Buy,” with an average price target of $13.50, despite Weiss Ratings downgrading the stock to “sell.”
• ACRV shares opened at $1.85, giving the company a market capitalization of about $79 million. Institutional investors and hedge funds own 71.62% of the stock, while Acrivon continues developing stapled peptide therapies, including a KRAS G12C-targeting candidate in early clinical trials.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Equities research analysts at HC Wainwright lifted their FY2030 earnings per share estimates for Acrivon Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of $0.14 per share for the year, up from their prior forecast of $0.13. The consensus estimate for Acrivon Therapeutics' current full-year earnings is ($1.92) per share.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.07.

Separately, Weiss Ratings downgraded shares of Acrivon Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $13.50.

Acrivon Therapeutics Stock Performance

Acrivon Therapeutics stock opened at $1.85 on Friday. The stock's 50 day moving average price is $1.67 and its 200 day moving average price is $1.68. The firm has a market capitalization of $79.18 million, a PE ratio of -0.98 and a beta of 1.85. Acrivon Therapeutics has a one year low of $1.26 and a one year high of $3.56.

Institutional Trading of Acrivon Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC increased its position in shares of Acrivon Therapeutics by 18.3% in the 4th quarter. Jane Street Group LLC now owns 342,071 shares of the company's stock worth $824,000 after purchasing an additional 52,823 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Acrivon Therapeutics by 504.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 119,422 shares of the company's stock worth $288,000 after acquiring an additional 99,680 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Acrivon Therapeutics by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 198,223 shares of the company's stock valued at $478,000 after acquiring an additional 6,190 shares during the last quarter. Algert Global LLC bought a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at approximately $81,000. Finally, Two Sigma Investments LP raised its position in shares of Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock valued at $578,000 after acquiring an additional 138,033 shares in the last quarter. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source